Cargando…
Stakeholder views of managed entry agreements: A literature review of national studies
Access to highly expensive and innovative medicine is a challenge. Managed entry agreements/ arrangements (MEAs) consist of various forms of confidential agreements between pharmaceutical manufacturers and payers (hospitals, social insurance), which are mainly negotiated when there is uncertainty of...
Autores principales: | Thanimalai, Subramaniam, Choon, Wai Yee, Lee, Kenneth Kwing-Chin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297797/ https://www.ncbi.nlm.nih.gov/pubmed/37383516 http://dx.doi.org/10.1016/j.hpopen.2021.100032 |
Ejemplares similares
-
How Do Iranian Stakeholders Think About Pharmaceutical Managed Entry Agreements?
por: Shobeiri, Nikta, et al.
Publicado: (2022) -
Managed entry agreements
por: Muscolo, Luisa AA, et al.
Publicado: (2014) -
Managed Entry Agreements for Pharmaceuticals in the Context of Adaptive Pathways in Europe
por: Bouvy, Jacoline C., et al.
Publicado: (2018) -
Introduction of managed entry agreements in Korea: Problem, policy, and politics
por: Kim, Hyungmin, et al.
Publicado: (2023) -
The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications
por: Ferrario, Alessandra, et al.
Publicado: (2017)